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Background: A novel concept of peri-stent contrast staining (PSS) is an angiographical finding that contrast medium stains outside the stent and 
might be related to IVUS findings of severe incomplete stent apposition. PSS is thought to be one of the risk factors for very late stent thrombosis 
(VLST). However, the association between the temporal change of PSS and the occurrence of VLST is unknown.
Methods: We retrospectively examined the association between the temporal change of PSS and the occurrence of VLST in patients who had 
undergone serial follow-up coronary angiography (CAG) after sirolimus eluting stent (SES) implantation. PSS is defined as vessel enlargement over 
20% of stent diameter with contrast medium staining outside the stent over. VLST is defined as the occurrence of acute myocardial infarction due to 
stent thrombosis confirmed with CAG at least one year after stent implantation.
Results: Between July 2004 and December 2009, we confirmed 86 patients with PSS after SES implantation who could be assessed the temporal 
change of PSS by serial follow-up CAG. The progression of PSS was found in 30 of the 86 patients (34.9%). The patients with progression of PSS had 
a significantly high prevalence of VLST compared with those without progression of PSS (10% vs. 0%, p<0.05).
Conclusions: The progression of PSS might be associated with the occurrence of VLST in patients 
after SES implantation. Serial follow-up CAG might be useful to identify the patients at high risk of VLST. 
